Accéder au contenu
Merck
Toutes les photos(1)

Documents

N3538

Sigma-Aldrich

Nateglinide

≥98% (HPLC), solid

Synonyme(s) :

Fastic, N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine, Starlix, Starsis

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H27NO3
Numéro CAS:
105816-04-4
Poids moléculaire :
317.42
Numéro MDL:
MFCD00875706
Code UNSPSC :
12352200
ID de substance PubChem :
329818636
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

solid

Couleur

white to off-white

Solubilité

DMSO: >5 mg/mL
H2O: insoluble

Auteur

Novartis

Température de stockage

room temp

Chaîne SMILES 

CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O

InChI

1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1

Clé InChI

OELFLUMRDSZNSF-BRWVUGGUSA-N

Informations sur le gène

human ... ABCC8(6833) , KCNJ11(3767)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Actions biochimiques/physiologiques

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.
Nateglinide is a short-acting insulin secretagogue useful in treating type 2 diabetes. It is an insulinotropic agent effective for postprandial hyperglycemia. Nateglinide restores prandial insulin levels in a glucose-dependent manner.

Caractéristiques et avantages

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Julia Kreis et al.
Health policy (Amsterdam, Netherlands), 104(1), 27-31 (2011-12-06)
In Germany, coverage decisions in the statutory health insurance (SHI) system are based on the principles of evidence-based medicine. Recently, an evidence assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) of the oral antidiabetics of the
Carola Saloranta et al.
The Journal of clinical endocrinology and metabolism, 87(9), 4171-4176 (2002-09-06)
Nateglinide is a fast-acting insulin secretion agent that specifically targets postprandial hyperglycemia in patients with type 2 diabetes. The recent reduction in the diagnostic criteria for diabetes and improved understanding of the importance of early insulin secretion served as the
Julio Rosenstock et al.
Diabetes care, 27(6), 1265-1270 (2004-05-27)
A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. Enrolled patients (n = 150) had received treatment with diet and
Toshiyuki Takanohashi et al.
European journal of drug metabolism and pharmacokinetics, 37(1), 9-15 (2011-10-21)
Nateglinide and mitiglinide are immediate short-acting insulinotropic agents. Both are administered preprandially to control postprandial hyperglycemia. Glinide drugs are characterized by immediate onset as well as rapid disappearance of effect as compared with sulfonylurea drugs. We examined the rapidity of
Jatinder Kaur et al.
Journal of medicinal chemistry, 55(17), 7883-7891 (2012-08-25)
A new group of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (13 and 18), 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (14 and 19), or nitrooxyethyl (15 and 20) moiety attached to the carboxylic acid group of the type II antidiabetic drugs nateglinide
Afficher tous les articles scientifiques apparentés

Articles

Potassium Channels

We offer many products related to potassium channels for your research needs.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique